Optical properties of the chemotherapy drugs used in the central nervous system lymphoma therapy: Monitoring drug delivery

T. Myllyla, Alexey Popov, L. Surazynski, J. Oinas, O. Bibikova, A. Bykov, M. S. Wrobel, M. Gnyba, M. Jedrzejewska-Szczerska, I. Meglinski, O. Kuittinen

Research output: Chapter in Book/Report/Conference proceedingConference article in proceedingsScientificpeer-review

1 Citation (Scopus)

Abstract

Our aim is to optically monitor the delivery of the chemotherapy drugs for brain tumours, particularly used in the central nervous system (CNS) lymphoma therapy. In vivo monitoring would help to optimize the treatment and avoiding unnecessary medications. Moreover, it would be beneficial to be able to measure which of the multi-regimen drugs actually do penetrate and how well into the brain tissue. There exist several potential optical measurement techniques to be utilised for the purpose. The most desired method would allow the detection of the drugs without using optical biomarkers as a contrast agent. In this case, for non-invasive sensing of the drug in the brain cortex, the drug should have a reasonably strong optical absorption band somewhere in the range between 600 nm and 1700 nm, and not directly coincident with the strong bands of haemoglobin or water. Alternatively, mid-infrared (MIR) range has the potential for invasive drug monitoring techniques. In this paper, we report the optical properties of several chemotherapy drugs used in CNS lymphoma therapy, such as rituximabi, cyclophosphamide and etoposide. We measured their transmittance and reflectance spectra in near-infrared (NIR) range, particularly 900 nm-2500 nm, to be considered when choosing the in vivo monitoring method to be developed. The absorption and scattering coefficients were retrieved from the measurements and applying Beer's law. For the measurement of the sum of total transmission and reflection in NIR range we used integrating sphere with spektralo to enable calculation of the scattering coefficient.

Original languageEnglish
Title of host publicationNovel Biophotonics Techniques and Applications III
EditorsArjen Amelink, I. Alex Vitkin
PublisherInternational Society for Optics and Photonics SPIE
ISBN (Print)978-1-6284-1705-0
DOIs
Publication statusPublished - 1 Jan 2015
MoE publication typeNot Eligible
EventNovel Biophotonics Techniques and Applications III - Munich, Germany
Duration: 24 Jun 201525 Jun 2015

Publication series

SeriesProgress in Biomedical Optics and Imaging
Number58
Volume16
ISSN1605-7422
SeriesProceedings of SPIE
Volume9540
ISSN0277-786X

Conference

ConferenceNovel Biophotonics Techniques and Applications III
CountryGermany
CityMunich
Period24/06/1525/06/15

Keywords

  • Chemotherapy drugs
  • cyclophosphamide
  • etoposide
  • near-infrared spectroscopy
  • optical properties.
  • rituximabi

Fingerprint Dive into the research topics of 'Optical properties of the chemotherapy drugs used in the central nervous system lymphoma therapy: Monitoring drug delivery'. Together they form a unique fingerprint.

  • Cite this

    Myllyla, T., Popov, A., Surazynski, L., Oinas, J., Bibikova, O., Bykov, A., Wrobel, M. S., Gnyba, M., Jedrzejewska-Szczerska, M., Meglinski, I., & Kuittinen, O. (2015). Optical properties of the chemotherapy drugs used in the central nervous system lymphoma therapy: Monitoring drug delivery. In A. Amelink, & I. A. Vitkin (Eds.), Novel Biophotonics Techniques and Applications III [95400Q] International Society for Optics and Photonics SPIE. Progress in Biomedical Optics and Imaging, No. 58, Vol.. 16, Proceedings of SPIE, Vol.. 9540 https://doi.org/10.1117/12.2183765